Article
Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study.
Targeted oncology - 1 Jul 2021
Callejo Almudena, Faouzi Sara, Bouché Olivier, Bertucci François, Chevalier Thomas, Isambert Nicolas, Duffaud Florence, Collard Olivier, Penel Nicolas, Terrier Philippe, Mir Olivier, Blay Jean Yves, Le Cesne Axel
Abstract excerpt
BACKGROUND: Retrospective analyses suggest that patients with advanced KIT exon 9-mutated gastrointestinal stromal tumors (GISTs) receiving imatinib 800 mg (rather than 400 mg) daily have better outcomes. In the adjuvant setting, the question of the optimal dose of imatinib remains unsettled. OBJECTIVE: We aimed to retrospectively assess the activity of imatinib 400 mg in both the adjuvant and the advanced...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.